Dirk Brockstedt, Ph.D.

Dr. Brockstedt is senior vice president, Biology at FLX Bio, an immuno-oncology company focused on the discovery and development of small molecule drugs to activate the immune system and eradicate cancer. Prior to joining FLX Bio, Dr. Brockstedt was executive vice president of research and development for Aduro Biotech, an immunotherapy company. Previously, he held various positions at Cerus Corp., where he was a foundational member of the original immunotherapy group and served as a scientist at Aventis, where he developed novel cancer therapies. Dr. Brockstedt has co-authored 40 scientific papers and is a named inventor on five issued patents and several pending applications. He holds a degree in microbiology from the University of Kiel in Germany and completed doctoral and postdoctoral work at Stanford University and the Stanford School of Medicine.